The Global Influenza
Vaccines Market, by Vaccine Type (Trivalent Vaccines and Quadrivalent
Vaccines), by Virus Type (Influenza Virus A and Influenza Virus B), by Age
Group (Pediatrics and Adults) and by Region (North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa) estimated to be valued at US$
3,991.4 billion in 2017, and is projected to exhibit a CAGR of 4.4% over the
forecast period (2018 – 2026).
Rising pipeline product to come
up with new vaccine product as a part of key organic strategies by market
players. For instance, 2017, Seqirus’s FLAUD, first and only adjuvant-based
trivalent influenza vaccine, received MHRA approval against influenza virus in
older aged people (adults aged 65 and above). In same year, Seqirus entered in
the U.S market with its influenza vaccine portfolio, with over 50 million doses
for protection against seasonal influenza of 2017-2018. The portfolio includes
FLAUD, FLUCELVAX QUADRIVALENT, AFLURIA QUADRIVALENT, AFLURIA, and FLUVIRIN.
Moreover, in 2017, FluGen, Inc., received US$ 14.4 million by Department of
Defense for evaluating Universal Flu Vaccine, RedeeFlu, of Mismatched Strains.
In Sep 2017, Novavax initiating phase1/2 clinical trials for nanoparticle
seasonal influenza vaccine in older adults. In April 2018, BiodVax
Pharmaceuticals LTD., started enrollment of patients for phase 2 clinical
trials for universal flu vaccine candidate, M-001.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1705
Browse Market Data 32 Tables and
30 Figures spread through 150 Pages and in-depth TOC on "Influenza
Vaccines Market, by Vaccine Type (Trivalent Vaccines and Quadrivalent
Vaccines), by Virus Type (Influenza Virus A and Influenza Virus B), by Age
Group (Pediatrics and Adults) and by Region - Global Forecast to 2026”
Increasing prevalence of seasonal
influenza in pediatric population is propelling demands for development of new
vaccines. Influenza is estimated to infect 5% and 10% of adults and 20 to 30%
of children. Moreover, companies are engaged in producing vaccines through
innovative technologies such as egg-based, cell-based, and recombinant-based
product for reducing the gap between demand and supply. Furthermore, increasing
awareness and initiatives to increase the vaccine coverage is helping in market
growth. The 2017 – 2018 recommendations guidelines by the Advisory Committee on
Immunization Practices (ACIP) mentions routine annual influenza vaccination for
everyone aged older than 6 months. However, high cost of vaccine development is
expected to hinder growth of the market over the forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/influenza-vaccines-market-1705
Key takeaways of the Influenza
Vaccines Market:
The global influenza vaccines
market is expected to expand at a CAGR of 4.4% during the forecast period (2018
– 2026), owing to increasing R&D activities of market players.
Trivalent vaccine is expected to
dominate vaccine type segment, owing to more number of products
Influenza type A virus segment is
expected to be predominant, owing to increasing prevalence of type A based
infection
Pediatric being more susceptible
to influenza virus is expected to lead age group segment
Some of the major players
involved in global influenza vaccines market include Seqirus Vaccines Limited,
GlaxoSmithKline plc
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1705
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment